Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback